1. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Issue 2 (3rd May 2017) Authors: Ananthakrishnan, A. N; Sakuraba, A.; Barnes, E. L.; Pekow, J.; Raffals, L.; Long, M. D.; Sandler, R. S. Journal: Alimentary pharmacology & therapeutics Issue: Volume 46:Issue 2(2017) Page Start: 162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The features of mucosa‐associated microbiota in primary sclerosing cholangitis. Issue 7 (9th February 2016) Authors: Torres, J.; Bao, X.; Goel, A.; Colombel, J.‐F.; Pekow, J.; Jabri, B.; Williams, K.M.; Castillo, A.; Odin, J.A.; Meckel, K.; Fasihuddin, F.; Peter, I.; Itzkowitz, S.; Hu, J. Journal: Alimentary pharmacology & therapeutics Issue: Volume 43:Issue 7(2016) Page Start: 790 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Issue 6 (29th January 2018) Authors: Christensen, B.; Micic, D.; Gibson, P. R.; Yarur, A.; Bellaguarda, E.; Corsello, P.; Gaetano, J. N.; Kinnucan, J.; Rao, V. L.; Reddy, S.; Singh, S.; Pekow, J.; Rubin, D. T. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 6(2018) Page Start: 753 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗